GlaxoSmithKline has committed $2.3 million to the New Zealand part of a large international medical trial of Avandia. This trial is looking at Avandia's potential for reducing the burden of cardiovascular disease in type 2 diabetes.
The New Zealand trial is intended to run for five years, and will include 50 patients.
Avandia is used to tackle insulin resistance, worldwide, and has shown promising results in reducing cardiovascular disease associated with diabetes.
The inclusion of New Zealand is a positive signal for New Zealand research, that has been praised by GSK's worldwide team for its high quality results.
